for the Period Ended 31 May 2022
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 May 2022
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 June 2021 to 31 May 2022
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2022 | 2021 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | ( |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Operating profit(or loss): | | |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
As at
Notes | 2022 | 2021 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Debtors: | 3 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 4 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Capital and reserves | |||
Called up share capital: | | | |
Profit and loss account: | | | |
Total Shareholders' funds: | | |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 May 2022
Basis of measurement and preparation
Turnover policy
Other accounting policies
for the Period Ended 31 May 2022
2022 | 2021 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 May 2022
2022 | 2021 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Total | | |
for the Period Ended 31 May 2022
2022 | 2021 | |
---|---|---|
£ | £ | |
Taxation and social security | | |
Other creditors | | |
Total | | |
Orion MedTech Ltd CIC Trustees Annual Report FY May 2021 - May 2022Company activity and impact statementThroughout the year May 2021 to May 2022, the Covid-19 pandemic continued to affect normal business activities for many of Orion Medtech’s NHS and academic stakeholders. Despite the ongoing challenges, the company has met its objectives to promote high quality healthcare in the UK during the financial year ending 31 May 2022 through the following activities:Orion MedTech continued to support academic research in the field of medicine by developing and maintaining a data collection platform and analysing anonymised clinical data for a study funded by the National Institute of Health Research (NIHR). The Global Health Research Group on Neurotrauma developed a multi-centre, international, prospective cohort study of patients undergoing emergency surgery for Traumatic Brain Injury which included contributions from 180 study sites in the UK and in lower and middle income countries. Academic and technical support was provided at no cost. Following on from successful academic outputs to which Orion MedTech contributed and collaborated in, Orion MedTech developed and launched a related study platform, this time to include a cohort of patients receiving surgical treatment for Spinal injury. As with the above study, this project aims to include data from UK NHS Trusts as well as lower and middle income countries, giving an equitable opportunity for high-quality data for local audit or research.During the year, an international registry to map the pre-hospital, acute in-hospital, and post-acute care of patients suffering Traumatic Brain Injury continued to be iteratively developed and made available worldwide, receiving endorsement from the World Federation of Neurosurgical Societies (WFNS).The pandemic continued to affect the capability of NHS Trusts to contribute to national registries that are hosted by Orion MedTech. Therefore benchmarking and quality assurance reports continued to be scaled down or paused so as not to increase the pressure on overloaded staff and clinicians.Orion MedTech continues to work with the Medicines and Healthcare products Regulatory Agency and manufacturers of medical implants to provide a data analysis service which allows post-market surveillance of medical devices and identification of adverse events related to implanted devices in UK patients.Orion MedTech continues to provide software solutions and support to 38 NHS Trusts, many of which are made available without charge, or at cost.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
16 February 2023
And signed on behalf of the board by:
Name: Dr. A Joannides
Status: Director